Cell Therapy Production Moves to Factory Floor
Assembly Lines Are Preparing to Churn out Safe, Reliable, and Affordable Constructs
Why Cardiology Is Ripe to Become the Next Frontier for Precision Medicine
Cardiovascular Disease Applications Are Set to Focus on Highly Individualized Variables for Therapy
Genome Editing B.C. (Before CRISPR)
Lasting Lessons from the “Old Testament”
Cell-Based, Cell-Free Patches for Cardio Repair
Cardiologists May Now Feel Differently about Quick Patch Ups
For full access to this article login to GEN Select now.
Synthetic Bio Not Yet Ready for the Market
Lab-Designed Calls and Pathways Take Genetic and Metabolic Engineering to Next Level
- In May of this year, the J. Craig Venter Institute (JCVI) announced it had created the first fully synthetic, self-replicating bacterial cell ( Mycoplasma nycoides JCVI-syn1.0). While this proof-of-concept demonstration of an “artificial life form” might raise justifiable fears about the dangers of unregulated or nefarious synthetic biology efforts, ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.